SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
Go back to SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus| Sagebrush Gold Ltd. (NASDAQ: SAGE) | Delayed: 8.68 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.68 | 52 Week High | $62.64 | |||
| Open | $8.68 | 52 Week Low | $26.28 | |||
| Day High | $8.68 | P/E | N/A | |||
| Day Low | $8.68 | EPS | $-0.94 | |||
| Volume | 333,870 | |||||
